GlassScriptPhysician profile
Robert C Wang
NPI 1568447175
$144,175.65
in general payments reported to CMS, 2019-2025
25 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $15K · 2021: $8,210 · 2022: $18K · 2023: $28K · 2024: $11K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Honoraria: $12K · Food and Beverage: $8,525 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,475 · Travel and Lodging: $1,563 · Education: $35.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,420.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,240.00 |
| Honoraria | $12,415.00 |
| Food and Beverage | $8,524.61 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,475.00 |
| Travel and Lodging | $1,562.74 |
| Education | $35.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $27,749.73 | 2019 | |
| Eyepoint US, INC. | $23,931.24 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $23,414.43 | 2022-2025 | Xipere |
| Genentech USA, INC. | $21,028.42 | 2019-2024 | Vabysmo, Susvimo, Lucentis |
| Mallinckrodt Hospital Products INC. | $18,647.63 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $11,467.79 | 2022-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Abbvie INC. | $4,478.35 | 2019-2025 | Ozurdex |
| Harrow Eye, LLC | $3,314.71 | 2025 | Iheezo, Triesence |
| Alimera Sciences, INC. | $3,279.89 | 2019-2024 | Iluvien, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,615.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $1,351.39 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $929.38 | 2019-2025 | Eylea Hd, Eylea |
| Genentech, INC. | $919.98 | 2019-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $833.51 | 2022-2025 | Syfovre |
| Coherus Oncology, INC. | $401.05 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $217.94 | 2024 | Izervay |
| Astellas Pharma US INC | $183.05 | 2024-2025 | Izervay |
| Horizon Therapeutics Plc | $121.74 | 2021-2023 | Tepezza |
| Allergan, INC. | $98.72 | 2020-2021 | |
| Sandoz INC. | $74.05 | 2024 | Cimerli |
| Vyera Pharmaceuticals, LLC | $33.21 | 2021-2022 | |
| Amgen INC. | $25.96 | 2025 | Tavneos |
| Biotissue Holdings INC. | $25.59 | 2025 | |
| Kala Pharmaceuticals, INC. | $18.56 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.